AU2011367817B2 - Recombinant subunit dengue virus vaccine - Google Patents

Recombinant subunit dengue virus vaccine Download PDF

Info

Publication number
AU2011367817B2
AU2011367817B2 AU2011367817A AU2011367817A AU2011367817B2 AU 2011367817 B2 AU2011367817 B2 AU 2011367817B2 AU 2011367817 A AU2011367817 A AU 2011367817A AU 2011367817 A AU2011367817 A AU 2011367817A AU 2011367817 B2 AU2011367817 B2 AU 2011367817B2
Authority
AU
Australia
Prior art keywords
den4
dengue
vaccine
protein
den3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011367817A
Other languages
English (en)
Other versions
AU2011367817A1 (en
Inventor
Andrew J. Bett
Beth-Ann Griswold COLLER
Timothy MARTYAK
Vidya B. Pai
D. Elliot Parks
Michele YELMENE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2011367817A1 publication Critical patent/AU2011367817A1/en
Application granted granted Critical
Publication of AU2011367817B2 publication Critical patent/AU2011367817B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2011367817A 2010-10-29 2011-10-27 Recombinant subunit dengue virus vaccine Ceased AU2011367817B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40831010P 2010-10-29 2010-10-29
US61/408,310 2010-10-29
PCT/US2011/058026 WO2012154202A1 (en) 2010-10-29 2011-10-27 Recombinant subunit dengue virus vaccine

Publications (2)

Publication Number Publication Date
AU2011367817A1 AU2011367817A1 (en) 2013-04-18
AU2011367817B2 true AU2011367817B2 (en) 2015-05-28

Family

ID=47139466

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011367817A Ceased AU2011367817B2 (en) 2010-10-29 2011-10-27 Recombinant subunit dengue virus vaccine

Country Status (10)

Country Link
US (2) US9198964B2 (enExample)
EP (1) EP2632485A4 (enExample)
JP (1) JP6018575B2 (enExample)
KR (1) KR20130138789A (enExample)
AU (1) AU2011367817B2 (enExample)
BR (1) BR112013009649A2 (enExample)
MX (1) MX344596B (enExample)
MY (1) MY166534A (enExample)
SG (3) SG10201508700XA (enExample)
WO (1) WO2012154202A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238734B2 (en) * 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012154202A1 (en) 2010-10-29 2012-11-15 Merck Sharp & Dohme Corp. Recombinant subunit dengue virus vaccine
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9861692B2 (en) 2013-06-21 2018-01-09 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
MX383329B (es) 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
US11241491B2 (en) 2017-05-23 2022-02-08 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus serotype 4 epitopes
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
JP7382634B2 (ja) 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
MX2020008766A (es) * 2018-02-22 2020-12-07 Sanofi Aventis Deutschland Variantes de tripsina porcina.
EP3836962B1 (en) * 2018-08-14 2024-11-27 Merck Sharp & Dohme LLC A virus neutralization assay utilizing imaging cytometry
KR102301130B1 (ko) * 2018-12-27 2021-09-15 주식회사 이뮨메드 뎅기출혈열 진단 키트

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
CA2224724C (en) * 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
KR20010022452A (ko) * 1997-07-31 2001-03-15 추후제출 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US20040213808A1 (en) 2002-12-11 2004-10-28 Michael Lieberman Recombinant vaccine against flavivirus infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
CA2721657A1 (en) 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
WO2012154202A1 (en) 2010-10-29 2012-11-15 Merck Sharp & Dohme Corp. Recombinant subunit dengue virus vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VOLK ET AL, VIROLOGY, 20 JULY 2007, VOL 364, NO 1, PAGES 147-154 *
WATT ET AL, CLIN INFECT DIS, 15 APRIL 2003, VOL 36, NO 8, PAGES 1067-1069 *

Also Published As

Publication number Publication date
EP2632485A4 (en) 2014-05-28
US9198964B2 (en) 2015-12-01
JP6018575B2 (ja) 2016-11-02
EP2632485A1 (en) 2013-09-04
AU2011367817A1 (en) 2013-04-18
US10137187B2 (en) 2018-11-27
MY166534A (en) 2018-07-10
SG10201508700XA (en) 2015-11-27
MX2013004741A (es) 2013-06-05
WO2012154202A1 (en) 2012-11-15
JP2013542224A (ja) 2013-11-21
SG189048A1 (en) 2013-05-31
MX344596B (es) 2016-12-20
US20160074502A1 (en) 2016-03-17
KR20130138789A (ko) 2013-12-19
BR112013009649A2 (pt) 2016-07-12
SG10201801947YA (en) 2018-04-27
US20130216575A1 (en) 2013-08-22
CN103179983A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
AU2011367817B2 (en) Recombinant subunit dengue virus vaccine
AU2010257162B2 (en) Recombinant subunit West Nile virus vaccine for protections of human subjects
Fahimi et al. Dengue viruses and promising envelope protein domain III-based vaccines
WO2001003729A2 (en) Recombinant envelope vaccine against flavivirus infection
EP3481849B1 (en) Chimeric dengue/zika viruses as live-attenuated zika virus vaccines
US9861692B2 (en) Dengue virus vaccine compositions and methods of use thereof
US10449243B2 (en) Dengue virus vaccine compositions and methods of use thereof
Liu Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine
US20040213808A1 (en) Recombinant vaccine against flavivirus infection
US20050287170A1 (en) Subunit vaccine against West Nile viral infection
CN103179983B (zh) 重组亚单位登革病毒疫苗
Pai Weeks-levy, Carolyn, L Ogata, Steven, A

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired